120 related articles for article (PubMed ID: 20619093)
1. [The clinical significance of changes in CD4+ T cell counts by peripheral blood from patients with pulmonary tuberculosis after antitubercular treatment].
Li DX; Zhang TT; Tan SY; Xiao P; Tan YJ; Zhang XL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Jul; 26(7):679-81, 684. PubMed ID: 20619093
[TBL] [Abstract][Full Text] [Related]
2. Comparison of CD4 and CD8 lymphocyte counts in HIV-negative pulmonary TB patients with those in normal blood donors and the effect of antitubercular treatment: hospital-based flow cytometric study.
Uppal SS; Tewari SC; Verma S; Dhot PS
Cytometry B Clin Cytom; 2004 Sep; 61(1):20-6. PubMed ID: 15351978
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection.
Pilheu JA; De Salvo MC; Gonzalez J; Rey D; Elias MC; Ruppi MC
Int J Tuberc Lung Dis; 1997 Oct; 1(5):422-6. PubMed ID: 9441096
[TBL] [Abstract][Full Text] [Related]
4. [The change and the clinical significance of peripheral blood Th1/Th2 cells in patients with pulmonary tuberculosis].
Tan YJ; Zhang YB; Feng DY; Xie B; Lin ZY; Chen HG; Li YG
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Jun; 27(6):385-9. PubMed ID: 15256086
[TBL] [Abstract][Full Text] [Related]
5. Association of mycobacterial antigen-specific CD4(+) memory T cell subsets with outcome of pulmonary tuberculosis.
Wang X; Cao Z; Jiang J; Niu H; Dong M; Tong A; Cheng X
J Infect; 2010 Feb; 60(2):133-9. PubMed ID: 19878691
[TBL] [Abstract][Full Text] [Related]
6. Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.
Kalou M; Sassan-Morokro M; Abouya L; Bile C; Maurice C; Maran M; Tossou O; Roels T; Greenberg AE; Wiktor SZ; Nkengasong JN
J Med Virol; 2005 Feb; 75(2):202-8. PubMed ID: 15602734
[TBL] [Abstract][Full Text] [Related]
7. Cytokine profile in human immunodeficiency virus positive patients with and without tuberculosis.
Agarwal SK; Singh A; Anuradha S; Singh NP; Sokhi J; Baveja UK
J Assoc Physicians India; 2001 Aug; 49():799-802. PubMed ID: 11837467
[TBL] [Abstract][Full Text] [Related]
8. T-lymphocyte subpopulations in tuberculosis.
Swaminathan S; Nandini KS; Hanna LE; Somu N; Narayanan PR; Barnes PF
Indian Pediatr; 2000 May; 37(5):489-95. PubMed ID: 10820541
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral immunomodulator Dzherelo in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS.
Nikolaeva LG; Maystat TV; Pylypchuk VS; Volyanskii YL; Masyuk LA; Kutsyna GA
Int Immunopharmacol; 2008 Jun; 8(6):845-51. PubMed ID: 18442788
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the significance of CD4+ T lymphocytes in the development of tuberculosis].
Yamamoto S; Wada M; Toida I
Kekkaku; 1993 Jan; 68(1):13-21. PubMed ID: 8094767
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological markers in Kenyan pulmonary tuberculosis patients with and without HIV-1.
Kivihya-Ndugga LE; Ochola JJ; Otieno G; Muthami LN; Gathua S
East Afr Med J; 1994 Jun; 71(6):373-5. PubMed ID: 7835258
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine and lamivudine: results of phase III studies.
Staszewski S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
Morris L; Martin DJ; Bredell H; Nyoka SN; Sacks L; Pendle S; Page-Shipp L; Karp CL; Sterling TR; Quinn TC; Chaisson RE
J Infect Dis; 2003 Jun; 187(12):1967-71. PubMed ID: 12792875
[TBL] [Abstract][Full Text] [Related]
14. [Changes and significance of peripheral blood T cell subsets, soluble interleukin-2 receptor and interferon-gamma in patients with retreatment pulmonary tuberculosis and initial treatment tuberculosis].
Zhang SJ; Xiao HP
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Dec; 34(12):884-7. PubMed ID: 22333498
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
[TBL] [Abstract][Full Text] [Related]
16. [Flow cytometric analysis of peripheral T lymphocytes from patients with mycobacterial diseases].
Wada M
Kekkaku; 1992 May; 67(5):393-407. PubMed ID: 1597937
[TBL] [Abstract][Full Text] [Related]
17. [Dynamics of T lymphocyte subsets in SARS patients].
Qiu ZF; Li TS; Fan HW; Han Y; Xie J; Wang AX; Deng GH
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):525-8. PubMed ID: 14650150
[TBL] [Abstract][Full Text] [Related]
18. [Immunity of middle age and aged patients with tuberculosis and its changes during multimodality treatment by using T-activin].
Adambekov DA; Litvinov VI; Mambetov KB; Koshmuratov AG; Sabyrbekova TS
Probl Tuberk; 1998; (5):46-8. PubMed ID: 9866400
[TBL] [Abstract][Full Text] [Related]
19. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
